HealthCapital Newsletter December 2018
HealthCapital Newsletter December 2018 If this newsletter is not displayed properly, please click here. Land Brandenburg und be Berlin
load images
HealthCapital Newsletter December 2018

Dear Sir or Madam,

For a number of years now, more than 50% of VC investments in Germany were made in Berlin. Digital solutions from the fintech and e-commerce segments have dominated in recent years. Now the life sciences seem to be following suit and we are pleased about two very significant financing rounds of Omeicos and AndrenoMed.

The HealthCapital Berlin-Brandenburg cluster is growing particularly rapidly in the development of digital solutions. More than 100 digital health startups were created in the last three years. While working towards “Digital Health City Berlin”, we took an important step with the Digital Summit Healthcare Industry to consolidate our leading position.

Precision medicine is also a big step towards the vision of a cure for disease. In our interview, Professor Nikolaus Rajewsky of the Berlin Institute for Medical Systems Biology explains how groundbreaking technologies in the LifeTime project should be combined to understand and predict the individual course of a disease in a patient. This will enable earlier diagnosis and more effective intervention.

In the coming year, we will continue to develop these and many other exciting topics in Berlin:
  • The DMEA (formerly conhIT) will be a highlight. Europe’s leading event for health IT from April 9-11, 2019 shows how modern IT improves quality of healthcare delivery and supports competitive institutions.
  • On May 7, 2019, BIONNALE will once again host the largest networking event for the health industry and life sciences in the capital region. The BIONNALE 2019 is a great opportunity to discuss the latest developments in biotechnology, pharmaceuticals, and medical technology with experts and key players in the industry.
  • Save the date for the World Health Summit as well, taking place October 27-29, 2019, where the most important actors from politics, science, and industry in Berlin will meet to discuss global health topics.
We wish you happy holidays, a successful start to the new year, and look forward to meeting you in 2019 in the capital region!

 
 

Interview

 
load images

PROF. DR. NIKOLAUS RAJEWSKY, BIMSB

Nikolaus Rajewsky studied mathematics and physics in his hometown of Cologne. After earning his doctorate, he spent time abroad in New Jersey and New York. In 2006, the 50-year-old returned to Germany and has since been Professor of Systems Biology at the Max Delbrück Center for Molecular Medicine (MDC) and at the Charité in Berlin. In 2008, he founded the Berlin Institute for Medical Systems Biology (BIMSB) as a new research unit at the MDC. In our interview, the award-winning researcher talks about the benefits of systems biology, European excellence, and disease prognoses.

Read more...

 

 

Business News

 

OMEICOS Therapeutics Closes €17m Series C Financing to Advance Lead Candidate OMT-28 Towards Pivotal Trials in Atrial Fibrillation

Proceeds provide OMEICOS with the financial runway to conduct the Phase II Study PROMISE-AF and continue expansion into ophthalmology through US subsidiary

Read more...

 

Adrenomed closes € 24 M financing led by Wellington and HBM

Adrenomed AG, the vascular integrity company, today announced the closing of a EUR 24 million series D financing round co-led by Wellington Partners and HBM Healthcare Investments as new investors. The new funds will be invested in the clinical development program of lead product candidate Adrecizumab. Adrecizumab is currently tested in a phase II clinical trial in patients with early septic shock and elevated plasma Adrenomedullin concentrations (bio-ADM®).

Read more...

 

Sphingotec raises €20 million from HBM and Wellington Partners

German diagnostics company sphingotec GmbH has closed a €20m growth equity financing round led by international healthcare specialist investors HBM and Wellington Partners.

Read more...

 

FDA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome

» more
 

NOXXON announces EUR 6.2 million equity capital raise including US$ 5 million from US family office - Acuitas Capital, LLC

» more
 

Clariness today announced it has acquired Viomedo, a leading online platform for clinical trials and provider of patient enrollment services

» more
 

MOLOGEN and ONCOLOGIE: Global assignment and codevelopment agreement relating to MOLOGEN’s lead compound lefitolimod

» more
 

Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide

» more
 

RaySearch and Eckert & Ziegler BEBIG enter into partnership regarding brachytherapy

» more
 

Interview: Peter Albiez, Country Manager, Pfizer Germany

» more
 
 

Science and Technology News

 

EU-OPENSCREEN achieves European Research Infrastructure status – fewer barriers in the search for new compounds

The European Commission awards the EU-OPENSCREEN consortium the coveted status of European Research Infrastructure Consortium (ERIC). The consortium brings together the infrastructure of 20 research institutes from currently seven European countries. The ERIC certificate is being presented on 25 September 2018 during a ceremony at the Berlin-Buch research campus.

Read more...

 

ERC Synergy Grant awarded to project exploring playful learning

Implementing a project entitled ‘BrainPlay’, an interdisciplinary team of researchers will explore the way in which play affects the human brain. Researchers from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health (BIH), Humboldt-Universität zu Berlin and the University of Geneva will study the effects of play on the learning processes inside the brain. The project has been awarded an ERC Synergy Grant by the European Research Council (ERC) amounting to €9.8 million Euros over a duration of six years.

Read more...

 

Charité Global Health – a new center for global health

Charité Global Health was established to improve global health care delivery. Founded by Charité – Universitätsmedizin Berlin, and with responsibility over both the coordination and development of Charité’s portfolio of global health projects, the interdisciplinary center will act as an interface with both internal and external visibility. Furthermore, it will focus on collaborations with national as well as international partners from the fields of research, politics and business.

Read more...

 

Developing innovative solutions that will ensure a safe use of CRISPR-Cas9

» more
 

Digital Health Summit Berlin awards innovative startups

» more
 

Revolutionizing the production of novel diagnostics with cost-effective Roll-to-Roll imprinting

» more
 
 

Technology and Cooperation Offers

 

Layer-by-Layer nanoscale coatings, surface modification, micro encapsulation and bead based microsensors for co-development of innovative applications

» more
 

Rapid and Specific Detection of most common Fungal Nail and Skin Infections

» more
 

Preventing Vascular Calcification in Chronic Kidney Disease

» more
 


For more news from the cluster healthcare industries click here.

 

Events

 
load images
 
05.12.2018

From patient-centric to human-centric in healthcare

» mehr
 
24. - 25.01.2019

2nd German Mass Cytometry User Forum

» more
 
24. - 26.02.2019

1st Immunology & Inflammation (I & I) Conference

» mehr
 
25. - 26.02.2019

12th Annual European Life Sciences CEO Forum

» more
 
09. - 11.04.2019

DMEA - Connecting Digital Health

» mehr
 
28. - 30.04.2019

IMTJ Medical Travel Summit 2019

» more
 
07.05.2019

BIONNALE 2019

» more
 
27. - 29.10.2019

World Health Summit

» more
 


For more events in the life science region Berlin-Brandenburg click here.



Imprint

The operator and party responsible for content in compliance with § 5 of the German Teleservices Act (TaMG) and in the meaning of the German Press Act:

Berlin Partner for Business and Technology GmbH
Fasanenstraße 85 | 10623 Berlin, Germany
Telephone: +49 30 46302-500
E-Mail: info (at) healthcapital.de

Commercial Registry Entry
Entered in the commercial registry of the Charlottenburg District Court,
Registration number: HRB 13072 B
VAT ID: DE 136629780

CEO:
Dr. Stefan Franzke

Chairman of the Supervisory Board:
Dr. Jürgen Allerkamp 

© 2018 Berlin Partner für Wirtschaft und Technologie GmbH

Unsubscribe from the newsletter
The newsletter of the Cluster healthcare industries Berlin-Brandenburg is a project of Berlin Partner for Business and Technology. Funded by the federal state of Berlin and the European Regional Development fund through the Investitionsbank Berlin.

load images load images
load images